A/H1N1/09 Influenza is Associated With High Mortality in Liver Cirrhosis

Spectrum of respiratory viral infectionsin liver disease patients with cirrhosis admitted in critical care unit

“…Only a few studies done in our center have shown the prevalence of influenza virus and its impact on the clinical outcome of cirrhotic patients. [7,8,14] The current study has found that respiratory viral infections other than influenza virus infection are also an important etiology of pneumonia in liver disease patients with cirrhosis admitted in CCUs. Transmission dynamics and seasonal distribution of RVs are key importance in understanding and limiting burden of morbidity and mortality of pneumonia patients in CCUs.…”

“…[5,6] There are very few studies which have shown the influence of respiratory viruses (RVs) in clinical outcome of cirrhotic patients in CCU. [7][8][9] Till now, there is no published study showing the prevalence of RVs and their bacterial coinfections in cirrhotic patients admitted in CCU care. With this background, the purpose of the current study is to investigate the prevalence of RVs in cirrhotic patients with pneumonia and its impact on the clinical outcome of cirrhotic patients with pneumonia admitted in CCUs.…”

High rates of 30-day mortality in patients with cirrhosis and COVID-19

“…12 It has been reported that viral influenza may increase the risk of decompensation in patients with cirrhosis, and recently it was reported that even patients with stable liver disease were at a high risk of hepatic function deterioration during the H1N1 influenza virus pandemic of 2009. 13 In the study by Premkumar et al, 82% of patients with cirrhosis and A/H1N1/09 died of pneumonia and acute respiratory distress syndrome despite timely antiviral treatment, with the severity of both respiratory distress and kidney impairment being independent predictors of mortality. 13 Since data on COVID-19 in patients with cirrhosis are lacking, we performed a multicentre retrospective study to describe the demographic, clinical and biochemical characteristics of patients with cirrhosis and SARS-CoV-2 infection in the Lombardy region and their outcomes.…”

“…13 In the study by Premkumar et al, 82% of patients with cirrhosis and A/H1N1/09 died of pneumonia and acute respiratory distress syndrome despite timely antiviral treatment, with the severity of both respiratory distress and kidney impairment being independent predictors of mortality. 13 Since data on COVID-19 in patients with cirrhosis are lacking, we performed a multicentre retrospective study to describe the demographic, clinical and biochemical characteristics of patients with cirrhosis and SARS-CoV-2 infection in the Lombardy region and their outcomes.…”

“…Progression of pre-existing portal thrombosis was ascertained in 1 patient, despite LMWH use. Patients in thromboprophylaxis vs. those untreated were comparable in terms of INR (1.23 [1.09-1.55] vs. 1.45 [1.21-1.54]; p = 0.97) and platelet count (132,000 [85,000-183,000] vs. 89,000 [34,500-136,000] per microliter, p = 0.064), more frequently had wellcompensated cirrhosis (Child-Pugh A in 51% vs. 18%, p = 0.05), and less frequently oesophageal varices (42% vs. 81%, p = 0.023).At data-lock (April, 30), among the 48 hospitalized patients, 17 (35%) died during hospital stay, 24 (50%) were discharged home after recovery (median length of stay 15[10][11][12][13][14][15][16][17][18][19][20][21][22][23] days), and 7 (15%) were still hospitalized (median length of stay at data-lock 15 days).…”